Incidence and Outcome of Breast Biopsy Procedures During Follow-up After Treatment for Breast Cancer

Parra, Raquel F. D. van la; Liao, Kaiping; Smith, Benjamin D.; Yang, Wei Tse; Leung, Jessica; Giordano, Sharon H.; Kuerer, Henry Mark

doi:10.1001/jamasurg.2017.5572

Cited by 9 publications

(3 citation statements)

References 37 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We used the 2008-2013 Truven MarketScan claims databases to identify a study cohort representative of the community practice setting. MarketScan data are from one of the largest US-based proprietary claims databases, covering nearly 240 million unique patients since 1995 and widely used in medical and health services research . MarketScan databases capture medical information on the full continuum of care in all settings, including inpatient and outpatient services and outpatient prescription drugs.…”

Section: Methodsmentioning

confidence: 99%

Complication Rates and Downstream Medical Costs Associated With Invasive Diagnostic Procedures for Lung Abnormalities in the Community Setting

Huo

Sheu

et al. 2019

JAMA Intern Med

View full text Add to dashboard Cite

Services added lung cancer screening with low-dose computed tomography (LDCT) as a Medicare preventive service benefit in 2015 following findings from the National Lung Screening Trial (NLST) that showed a 16% reduction in lung cancer mortality associated with LDCT. A challenge in developing and promoting a national lung cancer screening program is the high false-positive rate of LDCT because abnormal findings from thoracic imaging often trigger subsequent invasive diagnostic procedures and could lead to postprocedural complications. OBJECTIVE To determine the complication rates and downstream medical costs associated with invasive diagnostic procedures performed for identification of lung abnormalities in the community setting. DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study of non-protocol-driven community practices captured in MarketScan Commercial Claims & Encounters and Medicare supplemental databases was conducted. A nationally representative sample of 344 510 patients aged 55 to 77 years who underwent invasive diagnostic procedures between 2008 and 2013 was included. MAIN OUTCOMES AND MEASURES One-year complication rates were calculated for 4 groups of invasive diagnostic procedures. The complication rates and costs were further stratified by age group. RESULTS Of the 344 510 individuals aged 55 to 77 years included in the study, 174 702 comprised the study group (109 363 [62.6%] women) and 169 808 served as the control group (106 007 [62.4%] women). The estimated complication rate was 22.2% (95% CI, 21.7%-22.7%) for individuals in the young age group and 23.8% (95% CI, 23.0%-24.6%) for those in the Medicare group; the rates were approximately twice as high as those reported in the NLST (9.

show abstract

Section: Methodsmentioning

confidence: 99%

Complication Rates and Downstream Medical Costs Associated With Invasive Diagnostic Procedures for Lung Abnormalities in the Community Setting

Huo

Sheu

et al. 2019

JAMA Intern Med

View full text Add to dashboard Cite

show abstract

“…In the presence of mammographic suspicious lesions which involve the need to obtain a histological diagnosis (BI-RADS 4 and 5) or the need for MRI, to assess the response to neoadjuvant chemotherapy, imaging should not be delayed if hospital and staffing conditions allow; lesions classified as BI-RADS 3 can wait until after the pandemic [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

Management of non-invasive tumours, benign tumours and breast cancer during the COVID-19 pandemic: recommendations based on a Latin American survey

Pendola¹,

Elizalde²,

Vargas³

et al. 2020

ecancer

View full text Add to dashboard Cite

Introduction: The COVID-19 pandemic has changed health systems across the world, both in general hospitals and in oncology institutes or centres. For cancer specialists, particularly breast cancer (BC), the COVID-19 pandemic represents a combination of challenges since the hospital resources and staff have become more limited; this has obliged oncology specialists to seek a consensus and establish which patients with BC require more urgent attention and which patients can wait until there is a better control of this pandemic. The health system in Latin America has some special characteristics; in some of the countries, there are shortages which limit access to several specialities (surgery, clinical oncology and radiotherapy) in some regions. Objective: After a systematic review of the most recent literature regarding the management of BC during the COVID-19 pandemic, the main objective is to understand the position of the different Latin American Societies of Mastology in terms of available alternatives for the treatment of BC. Methods: After carrying out a comprehensive and exhaustive search of the most recent guides on the management of BC during the COVID-19 pandemic, the board members of the Latin American Federation of Mastology invited, via email, different specialists, all experts in BC care, to complete an anonymous survey online. The survey was distributed between 30 and 10 May 2020. The survey included 27 questions on four topics: demographic information, consultations, imaging and treatment of BC. The questionnaire was sent and then distributed to various health specialists including breast surgeons, clinical oncologists, radiation oncologists and radiologists via the Presidents of the different Latin American Societies of Mastology in 18 countries. The results are summarised as tallies based on the number of responses to each question. Results: A total of 499 responses were received. The majority of the respondents were males (275 (55.11%)); 290 participants were over 45 years (58.11%). The questionnaire presented those surveyed with three possible answers (agree, disagree and neither agree nor disagree). The results reflect that there was consensus in the majority of situations presented. Only seven questions revealed disagreement among those responding. The results are presented as recommendations. Conclusion: The management of patients with BC presents unique challenges during the current world health situation produced by COVID-19 pandemic. Breast care specialists (surgical oncologists, breast care clinicians, clinical oncologists, radiation oncologists and radiologists) from 18 countries in Central and South America submitted through their responses and recommendations for the treatment of BC during the COVID-19 pandemic.

show abstract

“…In this issue of JAMA Surgery , van la Parra et al have attempted to address this issue by determining the frequency of breast biopsies in 2 large cohorts of patients with breast cancer diagnosed from January 1, 2000, through December 31, 2011, by using a commercial insurance database (MarketScan Commercial Claims and Encounters database; Truven Health Analytics) (41 510 patients) and the SEER-Medicare database (80 369 patients) . Overall, the 5- and 10-year biopsy rates were 14.7% and 23.4%, respectively, in the commercial insurance cohort and 11.8% and 14.9%, respectively, in the SEER-Medicare cohort.…”

mentioning

confidence: 99%

Association of Biopsy Procedures During Follow-up for Breast Cancer With Surgical Decision Making in Patients

Yip

2018

JAMA Surg

View full text Add to dashboard Cite

The 2 main options for the surgical management of breast cancer are breast-conserving surgery (BCS) with whole-breast irradiation (WBI) or mastectomy, together with some form of axillary staging. A 20-year follow-up of a randomized clinical trial comparing the 2 options showed no difference in overall survival. 1 Local recurrence in the ipsilateral breast was 14.3% in the group receiving BCS with WBI and 39.2% in those who did not receive radiotherapy. 1 Breast-conserving surgery with intraoperative radiotherapy has equivalent outcomes in patients with good prognostic features. 2 The 10-and 20-year actuarial rates of contralateral breast cancer were 6.1% and 12%, respectively, in the Surveillance, Epidemiology, and End Results (SEER) database. 3 Women who have received a unilateral mastectomy need an annual mammography on the intact breast, and those who have undergone BCS require bilateral mammography. 4 Surveillance is likely to identify breast lesions requiring a biopsy to rule out malignant disease. Little information is available on the biopsy rate after BCS or mastectomy.In this issue of JAMA Surgery, van la Parra et al 5 have attempted to address this issue by determining the frequency of breast biopsies in 2 large cohorts of patients with breast cancer diagnosed from January 1, 2000, through December 31, 2011, by using a commercial insurance database (MarketScan Commercial Claims and Encounters database; Truven Health Analytics) (41 510 patients) and the

show abstract

Incidence and Outcome of Breast Biopsy Procedures During Follow-up After Treatment for Breast Cancer

Abstract: These data on the need for breast biopsies during follow-up and subsequent treatments from a large cohort of women with commercial insurance and Medicare can be used in the context of therapy-planning discussions and survivorship expectations for patients with breast cancer.

Cited by 9 publications

References 37 publications

Complication Rates and Downstream Medical Costs Associated With Invasive Diagnostic Procedures for Lung Abnormalities in the Community Setting

Complication Rates and Downstream Medical Costs Associated With Invasive Diagnostic Procedures for Lung Abnormalities in the Community Setting

Management of non-invasive tumours, benign tumours and breast cancer during the COVID-19 pandemic: recommendations based on a Latin American survey

Association of Biopsy Procedures During Follow-up for Breast Cancer With Surgical Decision Making in Patients

Contact Info

Product

Resources

About